Chemours Company's income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Chemours Company reported revenue of $5.8B (+0.4% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net sales | $5.8B | $5.8B | $6.0B | $6.8B |
| Cost of goods sold | $4.9B | $4.6B | $4.7B | $5.2B |
| Gross profit | $902.0M | $1.2B | $1.3B | $1.6B |
| Selling, general, and administrative expense | $799.0M | $585.0M | $1.3B | $710.0M |
| Research and development expense | $108.0M | $109.0M | $108.0M | $118.0M |
| Restructuring, asset-related, and other charges | $59.0M | $60.0M | $153.0M | $16.0M |
| Goodwill impairment charge | $0 | $56.0M | — | — |
| Total other operating expenses | $966.0M | $810.0M | $1.6B | $844.0M |
| Equity in earnings of affiliates | $35.0M | $43.0M | $45.0M | $55.0M |
| Interest expense, net | ($269.0M) | ($264.0M) | ($208.0M) | ($163.0M) |
| Loss on extinguishment of debt | ($5.0M) | ($1.0M) | ($1.0M) | $7.0M |
| Other income, net | $26.0M | $8.0M | $91.0M | $70.0M |
| (Loss) Income before income taxes | ($277.0M) | $127.0M | ($318.0M) | $741.0M |
| (Benefit from) provision for income taxes | $109.0M | $41.0M | ($81.0M) | $163.0M |
| Net (loss) income | ($386.0M) | $86.0M | ($237.0M) | $578.0M |
| Net (loss) income attributable to Chemours | ($386.0M) | $86.0M | ($238.0M) | $578.0M |
| Basic (loss) earnings per share of common stock | -$2.57 | $0.58 | -$1.60 | $3.72 |
| Diluted (loss) earnings per share of common stock | -$2.57 | $0.57 | -$1.60 | $3.65 |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Net sales | $1.6B | $1.4B | $1.5B | $1.6B |
| Cost of goods sold | $1.3B | $1.2B | $1.3B | $1.3B |
| Gross profit | $286.0M | $212.0M | $233.0M | $278.0M |
| Selling, general, and administrative expense | $469.0M | $147.0M | $109.0M | $437.0M |
| Research and development expense | $27.0M | $26.0M | $26.0M | $28.0M |
| Restructuring, asset-related, and other charges | $3.0M | $13.0M | $4.0M | $18.0M |
| Total other operating expenses | $499.0M | $186.0M | $139.0M | $483.0M |
| Equity in earnings of affiliates | $9.0M | $8.0M | $9.0M | $9.0M |
| Interest expense, net | ($68.0M) | ($69.0M) | ($68.0M) | ($67.0M) |
| Loss on extinguishment of debt | ($2.0M) | ($9.0M) | — | — |
| Other income, net | $273.0M | $22.0M | $16.0M | $2.0M |
| Loss before income taxes | ($1.0M) | ($22.0M) | $51.0M | ($261.0M) |
| Provision for income taxes | $273.0M | ($7.0M) | ($9.0M) | $119.0M |
| Net loss | ($274.0M) | ($29.0M) | $60.0M | ($380.0M) |
| Less: Net income attributable to non-controlling interests | $0 | — | — | $1.0M |
| Net loss attributable to Chemours | ($274.0M) | ($29.0M) | $60.0M | ($381.0M) |
| Basic (loss) earnings per share of common stock | -$1.81 | -$0.19 | $0.40 | -$2.54 |
| Diluted (loss) earnings per share of common stock | -$1.81 | -$0.19 | $0.40 | -$2.54 |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $670.0M | $713.0M | $1.2B | $1.1B |
| Restricted cash and restricted cash equivalents | $2.0M | $0 | $604.0M | — |
| Accounts and notes receivable, net | $679.0M | $770.0M | $610.0M | $626.0M |
| Inventories | $1.6B | $1.5B | $1.4B | $1.4B |
| Prepaid expenses and other | $80.0M | $71.0M | $66.0M | $82.0M |
| Assets held for sale | $1.0M | — | — | — |
| Total current assets | $3.0B | $3.0B | $3.8B | $3.2B |
| Property, plant, and equipment | $9.9B | $9.6B | $9.4B | $9.4B |
| Less: Accumulated depreciation | ($6.8B) | ($6.4B) | ($6.2B) | ($6.2B) |
| Property, plant, and equipment, net | $3.1B | $3.2B | $3.2B | $3.2B |
| Operating lease right-of-use assets | $271.0M | $258.0M | $260.0M | $240.0M |
| Goodwill | $46.0M | $46.0M | $102.0M | $102.0M |
| Other intangible assets, net | $2.0M | $3.0M | $3.0M | $13.0M |
| Investments in affiliates | $160.0M | $152.0M | $158.0M | $175.0M |
| Assets held for sale, non-current | $21.0M | — | — | — |
| Restricted cash and restricted cash equivalents | $52.0M | $50.0M | — | $202.0M |
| Other assets | $751.0M | $797.0M | $677.0M | $523.0M |
| Total assets | $7.4B | $7.5B | $8.3B | $7.6B |
| Accounts payable | $954.0M | $1.1B | $1.2B | $1.3B |
| Compensation and other employee-related cost | $96.0M | $99.0M | $89.0M | $121.0M |
| Short-term and current maturities of long-term debt | $42.0M | $54.0M | $51.0M | $25.0M |
| Current environmental remediation | $88.0M | $115.0M | $129.0M | $194.0M |
| Other accrued liabilities | $506.0M | $393.0M | $1.1B | $300.0M |
| Total current liabilities | $1.7B | $1.8B | $2.5B | $1.9B |
| Long-term debt, net | $4.1B | $4.1B | $4.0B | $3.6B |
| Operating lease liabilities | $191.0M | $194.0M | $206.0M | $198.0M |
| Long-term environmental remediation | $530.0M | $456.0M | $461.0M | $474.0M |
| Deferred income taxes | $37.0M | $35.0M | $44.0M | $61.0M |
| Other liabilities | $588.0M | $368.0M | $328.0M | $319.0M |
| Total liabilities | $7.1B | $6.9B | $7.5B | $6.5B |
| Common stock (par value $0.01 per share; 810,000,000 shares authorized; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025; 198,300,033 shares issued and 149,428,431 shares outstanding at December 31, 2024) | $2000000.00 | $2000000.00 | $2000000.00 | $2000000.00 |
| Treasury stock, at cost (48,826,793 shares at December 31, 2025; 48,871,602 shares at December 31, 2024) | -1.8B | -1.8B | -1.8B | -1.7B |
| Additional paid-in capital | $1.1B | $1.1B | $1.0B | $1.0B |
| Retained earnings | $1.2B | $1.7B | $1.8B | $2.2B |
| Accumulated other comprehensive loss | ($244.0M) | ($367.0M) | ($274.0M) | ($343.0M) |
| Total Chemours stockholders’ equity | $250.0M | $604.0M | $737.0M | $1.1B |
| Non-controlling interests | $1.0M | $1.0M | $2.0M | — |
| Total equity | $251.0M | $605.0M | $739.0M | $1.1B |
| Total liabilities and equity | $7.4B | $7.5B | $8.3B | $7.6B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $671.0M | $563.0M | $613.0M | $502.0M |
| Restricted cash and restricted cash equivalents | $0 | $0 | — | — |
| Accounts and notes receivable, net | $907.0M | $759.0M | $947.0M | $959.0M |
| Inventories | $1.5B | $1.5B | $1.5B | $1.6B |
| Prepaid expenses and other | $63.0M | $69.0M | $78.0M | $58.0M |
| Assets held for sale | $1.0M | $1.0M | $22.0M | $23.0M |
| Total current assets | $3.1B | $2.9B | $3.2B | $3.1B |
| Property, plant, and equipment | $10.0B | $9.9B | $9.8B | $9.8B |
| Less: Accumulated depreciation | ($7.0B) | ($6.9B) | ($6.7B) | ($6.7B) |
| Property, plant, and equipment, net | $3.0B | $3.0B | $3.1B | $3.1B |
| Operating lease right-of-use assets | $270.0M | $274.0M | $281.0M | $281.0M |
| Goodwill | $46.0M | $46.0M | $46.0M | $46.0M |
| Other intangible assets, net | $2.0M | $2.0M | $2.0M | $2.0M |
| Investments in affiliates | $170.0M | $166.0M | $180.0M | $177.0M |
| Assets held for sale, non-current | $0 | $21.0M | — | — |
| Restricted cash and restricted cash equivalents | $52.0M | $52.0M | $52.0M | $51.0M |
| Other assets | $488.0M | $738.0M | $712.0M | $710.0M |
| Total assets | $7.2B | $7.3B | $7.6B | $7.5B |
| Accounts payable | $937.0M | $891.0M | $1.0B | $1.0B |
| Compensation and other employee-related cost | $83.0M | $122.0M | $97.0M | $79.0M |
| Short-term and current maturities of long-term debt | $34.0M | $37.0M | $52.0M | $38.0M |
| Current environmental remediation | $124.0M | $97.0M | $107.0M | $102.0M |
| Other accrued liabilities | $683.0M | $462.0M | $589.0M | $608.0M |
| Total current liabilities | $1.9B | $1.6B | $1.9B | $1.9B |
| Long-term debt, net | $3.8B | $4.1B | $4.1B | $4.1B |
| Operating lease liabilities | $191.0M | $192.0M | $203.0M | $206.0M |
| Long-term environmental remediation | $671.0M | $520.0M | $502.0M | $503.0M |
| Deferred income taxes | $64.0M | $40.0M | $18.0M | $23.0M |
| Other liabilities | $573.0M | $590.0M | $569.0M | $565.0M |
| Total liabilities | $7.2B | $7.1B | $7.3B | $7.2B |
| Common stock (par value $0.01 per share; 810,000,000 shares authorized; 199,276,562 shares issued and 150,463,268 shares outstanding at June 30, 2026; 198,720,786 shares issued and 149,893,993 shares outstanding at December 31, 2025) | $2000000.00 | $2000000.00 | $2000000.00 | $2000000.00 |
| Treasury stock, at cost (48,813,294 shares at June 30, 2026 and 48,826,793 at December 31, 2025) | -1.8B | -1.8B | -1.8B | -1.8B |
| Additional paid-in capital | $1.1B | $1.1B | $1.1B | $1.1B |
| Retained earnings | $891.0M | $1.2B | $1.3B | $1.3B |
| Accumulated other comprehensive loss | ($229.0M) | ($244.0M) | ($284.0M) | ($293.0M) |
| Total Chemours stockholders’ equity | ($49.0M) | $215.0M | $298.0M | $237.0M |
| Non-controlling interests | $1.0M | $1.0M | $2.0M | $2.0M |
| Total equity | ($48.0M) | $216.0M | $300.0M | $239.0M |
| Total liabilities and equity | $7.2B | $7.3B | $7.6B | $7.5B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net (loss) income | ($386.0M) | $86.0M | ($237.0M) | $578.0M |
| Depreciation and amortization | $340.0M | $301.0M | $307.0M | $291.0M |
| Gain on sales of assets and businesses, net | ($8.0M) | ($3.0M) | ($110.0M) | ($21.0M) |
| Equity in earnings of affiliates, net | ($7.0M) | ($1.0M) | $11.0M | ($22.0M) |
| Loss (gain) on extinguishment of debt | $5.0M | $1.0M | $1.0M | ($7.0M) |
| Amortization of debt issuance costs and issue discounts | $11.0M | $12.0M | $9.0M | $9.0M |
| Deferred tax provision (benefit) | $64.0M | ($27.0M) | ($158.0M) | $20.0M |
| Asset-related charges | $32.0M | $27.0M | $95.0M | $5.0M |
| Stock-based compensation expense | $21.0M | $15.0M | $18.0M | $27.0M |
| Net periodic pension (income) cost | ($2.0M) | $6.0M | $9.0M | $9.0M |
| Defined benefit plan contributions | ($2.0M) | ($12.0M) | ($10.0M) | ($10.0M) |
| Other operating charges and credits, net | $18.0M | ($42.0M) | $1.0M | ($21.0M) |
| Goodwill impairments | $0 | $56.0M | — | — |
| Accounts and notes receivable, net | $106.0M | ($152.0M) | ($10.0M) | $91.0M |
| Inventories and other current operating assets | ($106.0M) | ($146.0M) | $58.0M | ($390.0M) |
| Other non-current operating assets | $66.0M | ($98.0M) | — | — |
| Accounts payable | ($165.0M) | ($9.0M) | ($72.0M) | — |
| Other current operating liabilities | ($3.0M) | ($660.0M) | $642.0M | — |
| Non-current operating liabilities | $280.0M | $13.0M | $2.0M | — |
| Cash provided by (used for) operating activities | $264.0M | ($633.0M) | $556.0M | $754.0M |
| Purchases of property, plant, and equipment | ($213.0M) | ($360.0M) | ($370.0M) | ($307.0M) |
| Proceeds from sales of assets and businesses, net of cash divested | $7.0M | $3.0M | $143.0M | $33.0M |
| Foreign exchange contract settlements, net | ($1.0M) | $2.0M | ($8.0M) | $3.0M |
| Other investing activities | $1.0M | $2.0M | $6.0M | ($13.0M) |
| Cash used for investing activities | ($206.0M) | ($353.0M) | ($229.0M) | ($284.0M) |
| Proceeds from issuance of debt, net | $748.0M | $606.0M | $648.0M | — |
| Debt repayments | ($787.0M) | ($490.0M) | ($280.0M) | ($68.0M) |
| Payments of debt issuance costs | ($7.0M) | ($9.0M) | ($4.0M) | ($1.0M) |
| Payments on finance leases | ($14.0M) | ($12.0M) | ($11.0M) | ($11.0M) |
| Proceeds from supplier financing programs | $80.0M | $93.0M | $123.0M | — |
| Payments to supplier financing program | ($88.0M) | ($102.0M) | ($87.0M) | — |
| Payments related to tax withheld on vested stock awards | ($1.0M) | ($3.0M) | ($19.0M) | ($6.0M) |
| Payments of dividends to the Company's common shareholders | ($78.0M) | ($148.0M) | ($149.0M) | ($154.0M) |
| Other financing activities | $21.0M | $21.0M | — | — |
| Cash (used for) provided by financing activities | ($126.0M) | ($36.0M) | $172.0M | ($685.0M) |
| Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents | $29.0M | ($22.0M) | $4.0M | ($32.0M) |
| (Decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents | ($39.0M) | ($1.0B) | $503.0M | ($247.0M) |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents at January 1, | $763.0M | $1.8B | $1.3B | $1.6B |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents at December 31, | $724.0M | $763.0M | $1.8B | $1.3B |
| Interest, net of amounts capitalized | $251.0M | $267.0M | $223.0M | $164.0M |
| Income taxes, net of refunds | $74.0M | $73.0M | $54.0M | $131.0M |
| Purchases of property, plant, and equipment included in accounts payable | $33.0M | $88.0M | $82.0M | $79.0M |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net loss | ($303.0M) | ($29.0M) | ($324.0M) | ($384.0M) |
| Depreciation and amortization | $159.0M | $79.0M | $259.0M | $180.0M |
| Gain on sales of assets and businesses | ($266.0M) | — | ($8.0M) | ($1.0M) |
| Equity in earnings of affiliates, net | ($10.0M) | ($6.0M) | ($23.0M) | ($16.0M) |
| Loss on extinguishment of debt | $11.0M | $9.0M | — | — |
| Amortization of debt issuance costs and issue discounts | $5.0M | $3.0M | $9.0M | $6.0M |
| Deferred tax provision | $238.0M | ($11.0M) | $68.0M | $84.0M |
| Asset-related charges | $1.0M | $1.0M | $27.0M | $11.0M |
| Stock-based compensation expense | $14.0M | $7.0M | $17.0M | $12.0M |
| Net periodic pension (income) cost | ($1.0M) | $0 | ($1.0M) | — |
| Defined benefit plan contributions | ($1.0M) | ($1.0M) | ($2.0M) | ($8.0M) |
| Other operating charges and credits, net | ($9.0M) | ($14.0M) | $19.0M | $14.0M |
| Accounts and notes receivable, net | ($218.0M) | ($77.0M) | ($163.0M) | ($174.0M) |
| Inventories and other current operating assets | $114.0M | $32.0M | ($76.0M) | ($42.0M) |
| Other non-current operating assets | $53.0M | $17.0M | $70.0M | $64.0M |
| Accounts payable | ($12.0M) | ($58.0M) | ($79.0M) | ($87.0M) |
| Other current operating liabilities | $217.0M | $12.0M | $92.0M | $83.0M |
| Other non-current operating liabilities | $122.0M | ($8.0M) | $242.0M | $239.0M |
| Cash provided by (used for) operating activities | $114.0M | ($44.0M) | $127.0M | ($19.0M) |
| Purchases of property, plant, and equipment | ($93.0M) | ($49.0M) | ($168.0M) | ($127.0M) |
| Proceeds from life insurance policies | $1.0M | $1.0M | — | — |
| Proceeds from sales of assets and businesses | $294.0M | $7.0M | $7.0M | $1.0M |
| Foreign exchange contract settlements, net | ($7.0M) | ($3.0M) | ($3.0M) | ($2.0M) |
| Cash provided by (used for) investing activities | $195.0M | ($44.0M) | ($163.0M) | ($128.0M) |
| Proceeds from issuance of debt | $700.0M | $700.0M | $95.0M | $95.0M |
| Debt repayments | ($963.0M) | ($689.0M) | ($119.0M) | ($111.0M) |
| Payments on finance leases | ($5.0M) | ($3.0M) | ($12.0M) | ($7.0M) |
| Payments of debt issuance cost | ($10.0M) | ($10.0M) | ($4.0M) | ($4.0M) |
| Proceeds from supplier financing program | $32.0M | $16.0M | $64.0M | $47.0M |
| Payments to supplier financing program | ($31.0M) | ($14.0M) | ($70.0M) | ($53.0M) |
| Proceeds from exercised stock options, net | $3.0M | $2.0M | — | — |
| Payments related to tax withholdings on vested stock awards | ($2.0M) | ($2.0M) | ($1.0M) | ($1.0M) |
| Payments of dividends to the Company's common shareholders | ($26.0M) | ($13.0M) | ($63.0M) | ($50.0M) |
| Debt extinguishment payments | ($6.0M) | ($6.0M) | — | — |
| Cash used for financing activities | ($308.0M) | ($19.0M) | ($89.0M) | ($84.0M) |
| Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents | ($2.0M) | ($2.0M) | $27.0M | $21.0M |
| Decrease in cash, cash equivalents, restricted cash and restricted cash equivalents | ($1.0M) | ($109.0M) | ($98.0M) | ($210.0M) |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1, | $724.0M | $724.0M | $763.0M | $763.0M |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at June 30, | $723.0M | — | — | $553.0M |
| Purchases of property, plant, and equipment included in accounts payable | $26.0M | $27.0M | $28.0M | $26.0M |
Chemours Company score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.